Table 4.
Univariate analysis—significant factors associated with pCR.
| Variable | pCR | Non-pCR | Fisher’s Exact |
|---|---|---|---|
| Tumor Size | |||
| T1 | 10 (43%) | 13 (57%) | 0.020 |
| T2 | 34 (52%) | 31 (48%) | |
| T3 & T4 | 1 (0.1%) | 14 (99.9%) | |
| Nodal Status | |||
| Positive | 19 (35%) | 35 (65%) | 0.024 |
| Negative | 24 (53%) | 21 (47%) | |
| Stage | |||
| Stage I | 6 (67%) | 3 (33%) | 0.020 |
| Stage IIA | 25 (51%) | 24 (49%) | |
| Stage IIB | 11 (42%) | 15 (58%) | |
| Stage III | 3 (16%) | 16 (84%) | |
| ER | |||
| Positive | 8 (18%) | 37 (82%) | ≤0.0001 |
| Negative | 37 (64%) | 21 (36%) | |
| PR | |||
| Positive | 5 (13%) | 33 (86% | |
| Negative | 40 (61%) | 25 (38%) | ≤0.0001 |
| HER-2 | |||
| Positive | 9 (50%) | 9 (50%) | 0.6070 |
| Negative | 36 (42%) | 49 (58%) | |
| Biological type | |||
| Luminal | 3 (9%) | 29 (91%) | ≤0.0001 |
| HER-2 Positive | 9 (50%) | 9 (50%) | |
| TNBC | 33 (62%) | 20 (38%) | |
| Ki-67 | |||
| ≥40% | 29 (57%) | 22 (43%) | 0.0001 |
| 15–39% | 15 (41%) | 22 (59%) | |
| <15% | 0 (0%) | 13 (100%) | |
| CD3+ Cell density at Center of Tumor | |||
| CD3+ CT ≥ 1186.81 mm2 | 27 (68%) | 13 (33%) | |
| CD3+ CT < 1186.80 mm2 | 18 (29%) | 45 (71%) | 0.0002 |
| CD3+ Cell density—Invasive Margin * | |||
| CD3+ IM ≥ 1093.71 mm2 | 29 (63%) | 17 (37%) | |
| CD3+ IM < 1093.70 mm2 | 2 (7%) | 27 (93%) | ≤0.0001 |
| CD8+ Cell Density at Center of Tumor | |||
| CD8+ CT ≥ 324,51 mm2 | 35 (64%) | 20 (36%) | |
| CD8+ CT < 324,50 mm2 | 10 (21%) | 38 (79%) | ≤0.0001 |
| CD8+ Cell density—Invasive Margin * | |||
| CD8+ IM ≥ 431.51 mm2 | 26 (63%) | 15 (37%) | |
| CD8+ IM < 431.50 mm2 | 5 (15%) | 29 (85%) | ≤0.0001 |
| Immunoscore CR | |||
| High | 25 (69%) | 11 (31%) | ≤0.0001 |
| Intermediate | 4 (50%) | 4 (50%) | |
| Low | 2 (6%) | 29 (94%) | |
* Data on invasive margin were not available on 28 patients.